Partners are 41 national hospitals including the University of Tokyo Hospital and a 13 member company consortium comprising Eisai and Astellas. Methods comprise MRI, PET, genetic testing, biomarker studies in blood and cerebrospinal fluid and other. 200 patients 60 – 84 years old with mild cognitive impairment will be compared to 300 controls with no impairment over 3 years (J-ADNI2 study).

NEDO news release, November 27, 2013